Contemporary Oncology最新文献_第8页

Azacitidine in outpatient treatment – single center experience 阿扎胞苷在门诊治疗-单中心经验

Contemporary Oncology Pub Date : 2016-01-13 DOI: 10.5114/wo.2015.56653

J. Rybka, E. Stefanko, A. Bogucka-Fedorczuk, A. Butrym, R. Poręba, K. Kuliczkowski, T. Wróbel

{"title":"Azacitidine in outpatient treatment – single center experience","authors":"J. Rybka, E. Stefanko, A. Bogucka-Fedorczuk, A. Butrym, R. Poręba, K. Kuliczkowski, T. Wróbel","doi":"10.5114/wo.2015.56653","DOIUrl":"https://doi.org/10.5114/wo.2015.56653","url":null,"abstract":"Aim of the study Azacitidine is a hypomethylating agent which is used in the treatment of myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia. Because of good tolerance to the drug, azacitidine can be administered both during hospitalization and in an outpatient setting. The aim of our retrospective analysis was to assess the efficacy of azacitidine treatment in patients with a myelodysplastic syndrome and with acute myeloid leukemia who had received treatment in hospital and in an ambulatory care setting. Offsets in the course of azacitidine administration and discontinuations of treatment have a negative impact on patients’ response to the therapy. Material and methods The study included 31 patients. Sixteen patients received azacitidine in an ambulatory care setting, 15 patients within their hospitalization. Results A hematologic response was achieved in 48% of the patients. Forty-one percent of the cycles were delayed. In an outpatient setting, 62% of the cycles were administered systematically, while during hospitalization the patients received 54% of cycles on time. Administrative problems caused the delay of 26% of the cycles. Conclusions Azacitidine has a high tolerance level and a high safety profile which allows for its use in an outpatient care setting. Outpatient administration of azacitidine is feasible and safe without compromising efficacy.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"16 1","pages":"467 - 470"},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89412599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

VEGF-C expression is not a prognostic factor in locally advanced colon adenocarcinoma VEGF-C表达不是局部晚期结肠腺癌的预后因素

Contemporary Oncology Pub Date : 2016-01-13 DOI: 10.5114/wo.2015.56649

M. Szajewski, W. Kruszewski, J. Lakomy, Maciej Ciesielski, K. Kawecki, J. Szefel

{"title":"VEGF-C expression is not a prognostic factor in locally advanced colon adenocarcinoma","authors":"M. Szajewski, W. Kruszewski, J. Lakomy, Maciej Ciesielski, K. Kawecki, J. Szefel","doi":"10.5114/wo.2015.56649","DOIUrl":"https://doi.org/10.5114/wo.2015.56649","url":null,"abstract":"Aim of the study Evaluation of the relationships between increased expression of VEGF-C (vascular endothelial growth factor-C) and vessel density in the tumour-surrounding stroma, patient survival, and other conventional prognostic factors in patients with pT3-4 colon cancer. Material and methods Expression of VEGF-C and vessel density were immunohistochemically assessed in 104 specimens of primary, locally advanced (pT3-4) colon adenocarcinoma after surgical resection. Results A significant relationship was found between the expression of VEGF-C and increased vessel density in the tumour-surrounding stroma (p = 0.03). A relationship between VEGF-C expression and location of the tumour in the left side of the colon was also found (p = 0.003). Expression of VEGF-C was likely to occur in well-differentiated tumours. No relationship between patient overall survival and the expression level of VEGF-C in locally advanced colon cancer was observed. Conclusions The study results indicate that expression of VEGF-C in cells of locally advanced pT3-4 adenocarcinoma of the colon does not affect the survival time of the patients. Increased expression of VEGF-C is accompanied by a significant increase in vessel density in the pT3-4 tumour stroma. Increased expression of VEGF-C in cancer cells is related to the tumour location in the left side of the colon and better tumour differentiation.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"138 1","pages":"446 - 450"},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80271410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland 波兰低剂量胸部计算机断层扫描肺癌筛查的成本-效果分析

Contemporary Oncology Pub Date : 2015-12-30 DOI: 10.5114/wo.2015.56656

Małgorzata Kanarkiewicz, T. Szczęsny, J. Krysiński, A. Buciński, J. Kowalewski, Zbigniew Pawłowicz

{"title":"Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland","authors":"Małgorzata Kanarkiewicz, T. Szczęsny, J. Krysiński, A. Buciński, J. Kowalewski, Zbigniew Pawłowicz","doi":"10.5114/wo.2015.56656","DOIUrl":"https://doi.org/10.5114/wo.2015.56656","url":null,"abstract":"Aim of the study To determine the cost-effectiveness of lung cancer (LC) screening with low-dose computerised tomography of the chest, as compared to an approach without screening, reimbursed today by the National Health Fund (NHF) in Poland. Material and methods In order to analyse the current costs of diagnostic and therapeutic procedures of a model LC patient treated today, a model group consisting of 199 consecutive patients diagnosed and treated in the Oncology Centre in Bydgoszcz, Poland from January 2007 to April 2010 was used. The number and type of performed procedures in this group was obtained from the Polish Register of Neoplasms and the NHF. Only direct medical costs were analysed. To calculate the total costs of screening, diagnostics, and treatment of the hypothetical LC patient who would have cancer diagnosed with screening CT, data from the literature and costs calculated for the model group were used. Prices of procedures were obtained from the price list of the NHF on 30 April 2010 and did not change from that time until June 2014. One-way sensitivity analysis was performed. Results The average cost per LC patient, diagnosed and treated without screening, is 5567.50 EUR, and median LC-specific survival is one year. In the hypothetical LC patient with cancer diagnosed by screening, the average cost is 13689.35 EUR per LC patient, with a median LC-specific survival of at least seven years. A calculated incremental cost-effectiveness ratio (ICER) is 1353.64 EUR/year of life gained. Conclusions Lung cancer screening with low-dose CT would be highly cost-effective in Poland.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"1 1","pages":"480 - 486"},"PeriodicalIF":0.0,"publicationDate":"2015-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91008506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Low cost abiraterone 低成本阿比特龙

Contemporary Oncology Pub Date : 2015-12-23 DOI: 10.5114/wo.2015.56661

Diego Barreiro, Francisco Castro

引用次数: 0

Clinical experience in appendiceal neuroendocrine neoplasms 阑尾神经内分泌肿瘤的临床体会

Contemporary Oncology Pub Date : 2015-12-22 DOI: 10.5114/wo.2015.56008

C. Ozcelik, S. Turanli, N. Bozdogan, C. Dibekoğlu

{"title":"Clinical experience in appendiceal neuroendocrine neoplasms","authors":"C. Ozcelik, S. Turanli, N. Bozdogan, C. Dibekoğlu","doi":"10.5114/wo.2015.56008","DOIUrl":"https://doi.org/10.5114/wo.2015.56008","url":null,"abstract":"Aim of the study To analyse the incidence of appendiceal neuroendocrine neoplasms in appendectomy specimens and establish the epidemiological and histopathological features, treatment, and clinical course. Material and methods Between 2004 and 2013, 975 patients who underwent appendectomy in Ankara Oncology Education and Research Hospital were retrospectively analysed. Results Neuroendocrine neoplasm was detected in the nine of 975 (0.9%) patients. Neuroendocrine neoplasms were diagnosed in eight patients by appendectomy, which was performed because of the prediagnosis of acute appendicitis, and in one patient by the suspicious mass detection during surgical procedures that were done in the appendix for a different reason. Eight of the patients’ tumours were in the tip of the appendix, and one of the patients’ tumours was at the base of appendix. Tumour size in 77.8% of patients was equal or less than 1 cm, in 22.2% patients it was 1–2 cm. There was tumour invasion in the muscularis propria layer in four patients, in the serosa layer in three patients, and in the deep mesoappendix in two patients. Patients were followed for a median of 78 months. In the follow-up of patients who were operated because of colon cancer, metachronous colon tumour evolved. This patient died due to progressive disease. Other patients are still disease-free. Conclusions The diagnosis of neuroendocrine neoplasm is often incidentally done after appendectomy. Tumour size is important in determining the extent of disease and in the selection of the surgical method during operation.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"10 1","pages":"410 - 413"},"PeriodicalIF":0.0,"publicationDate":"2015-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82368454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Hematogenous muscular metastasis of NSCLC in FDG-PET/CT FDG-PET/CT对NSCLC血液肌肉转移的影响

Contemporary Oncology Pub Date : 2015-12-22 DOI: 10.5114/wo.2015.56009

H. Satoh, T. Tamura, K. Kagohashi

引用次数: 0

Variation in treatment modalities, costs and outcomes of rectal cancer patients in Poland 波兰直肠癌患者治疗方式、费用和结果的变化

Contemporary Oncology Pub Date : 2015-12-22 DOI: 10.5114/wo.2015.56010

K. Herman, A. Komorowski, W. Wysocki, J. Tabor, R. Herman, A. Śliwczyński

{"title":"Variation in treatment modalities, costs and outcomes of rectal cancer patients in Poland","authors":"K. Herman, A. Komorowski, W. Wysocki, J. Tabor, R. Herman, A. Śliwczyński","doi":"10.5114/wo.2015.56010","DOIUrl":"https://doi.org/10.5114/wo.2015.56010","url":null,"abstract":"Aim of the study To evaluate outcome, costs and treatment differences in rectal cancer patients between various regions in Poland. Material and methods Data from the Polish National Health Fund of all patients with rectal cancer diagnosed and treated between 2005 and 2007 were analyzed. Overall, relative 5-year survival and the percentage of patients receiving chemotherapy, radiotherapy and surgery were analyzed. The possible influence of cost of treatment per patient and mean number of rectal cancer patients per surgical oncologist were analyzed as well. Results In total 15,281 patients with rectal cancer were diagnosed and treated in Poland in 2005–2007 within the services of the National Health Fund. The overall, relative 5-year survival rate was 51.6%. Curative surgery was performed in 64.1% of patients. Radiotherapy and chemotherapy were used in 47.5% and 60.7% of patients, respectively. The mean cost of treatment of one rectal cancer patient was 32,800 PLN and there were 49.8 rectal cancer patients per specialist in surgical oncology. Important differences between regions were found in all these factors, but without a significant influence on survival. A correlation between numbers of patients per specialist in different voivodeships and survival rates was observed, as well as a correlation between percentage of surgical resection in voivodeships and survival rates (p = 0.07). Conclusions Results of treatment of colorectal cancer in Poland improved significantly during the last decade. There exist however, important disparities between regions in terms of method of treatment, costs and outcomes.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"1 1","pages":"400 - 409"},"PeriodicalIF":0.0,"publicationDate":"2015-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83078875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Evaluation of prognostic factors in the surgical treatment of pulmonary metastases 肺转移瘤手术治疗的预后因素评价

Contemporary Oncology Pub Date : 2015-12-22 DOI: 10.5114/wo.2015.56007

K. Pawełczyk, M. Marciniak, Piotr Błasiak, A. Rzechonek

{"title":"Evaluation of prognostic factors in the surgical treatment of pulmonary metastases","authors":"K. Pawełczyk, M. Marciniak, Piotr Błasiak, A. Rzechonek","doi":"10.5114/wo.2015.56007","DOIUrl":"https://doi.org/10.5114/wo.2015.56007","url":null,"abstract":"Aim of the study The resection of pulmonary metastases is a routine practice of thoracic surgery wards; however, clear protocols or prognostic factors defining the surgical treatment criteria are still not available. The aim of the study is to evaluate the prognostic factors associated with long-term survival in a group of patients who underwent resection of pulmonary metastases. Material and methods A retrospective analysis was conducted on a group of 250 patients admitted to the Wrocław Thoracic Surgery Centre for radical resection of pulmonary lesions in the years 1996–2010. Results The patients included in the study (n = 250) underwent 339 thoracotomies in total. The overall five-year survival was 52.8%. The univariate data analysis showed that the survival rate was significantly better in patients subjected to more than one thoracotomy (p = 0.01674). Among the other data, such as sex, tumour histology, disease-free interval (DFI) ≤ 12 and > 12 months, DFI ≤ 36 and > 36 months, age, number of tumours identified in CT and number of tumours subject to resection, operated side, resection type, radicality of resection, extent of lymphadenectomy, and adjuvant therapy, no statistical significance was observed in univariate and multivariate analysis (p > 0.05). Conclusions Outcomes of re-metastasectomy are satisfactory if patients meet the baseline criteria for surgical treatment. None of the evaluated factors potentially influencing the patient survival was demonstrated to have any prognostic value. Further research, including the biology of tumours with pulmonary metastases, is necessary to select the group of patients that will benefit most from surgical treatment.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"2 1","pages":"378 - 384"},"PeriodicalIF":0.0,"publicationDate":"2015-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87401138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study 神经内分泌肿瘤的治疗:基于单簧管研究的新建议

Contemporary Oncology Pub Date : 2015-12-22 DOI: 10.5114/wo.2015.56006

B. Kos-Kudła

引用次数: 22

Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer 补体因子H多态性rs1061170与吸烟对肺癌发病的影响

Contemporary Oncology Pub Date : 2015-12-08 DOI: 10.5114/wo.2015.56202

N. Ezzeldin, D. El-Lebedy, A. Darwish, Ahmed El-Bastawissy, A. Shalaby

{"title":"Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer","authors":"N. Ezzeldin, D. El-Lebedy, A. Darwish, Ahmed El-Bastawissy, A. Shalaby","doi":"10.5114/wo.2015.56202","DOIUrl":"https://doi.org/10.5114/wo.2015.56202","url":null,"abstract":"Aim of the study Complement factor H (CFH) has been known to inhibit the complement pathway and to contribute to tumour growth by suppressing the anti-tumour cell mediated response in cell lines from several malignancies. We examined the association of Try402His single nucleotide polymorphism in CFH gene with lung cancer and the interaction with cigarette smoking. Material and methods This case-control study included 80 primary lung cancer patients and 106 control subjects who were genotyped for Try402His (rs1061170) by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Results Variant genotypes (Tyr/His and His/His) were overpresented among patients compared to controls (p = 0.03, OR = 2.510, 95% CI: 1.068–5.899), and the frequency of variant H allele was significantly overexpressed in cases compared to controls (p = 0.021). Tyr/His genotype was identified in 100% of small cell lung cancer (SCLC) patients vs. 34.5% of non-SCLC (NSCLC), while 20.7% of NSCLC patients were homozygous for the variant allele (His/His) (p = 0.001). Binary logistic regression analysis revealed a 2.5 times greater estimated risk for NSCLC than for SCLC among variant allele carriers, and a 7.3-fold increased risk of lung cancer among variant allele smoking carriers vs. 1.3-fold increased risk among wild allele smoking carriers. Moreover, the stage of cancer positively correlated with smoking and pack-years in allele H carriers, and the correlation was stronger among those who were homozygous for it (His/His) than those who were heterozygous (Tyr/His). Conclusions CFH 402H variant is a smoking-related risk factor for lung cancer, particularly the NSCLC.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"26 1","pages":"441 - 445"},"PeriodicalIF":0.0,"publicationDate":"2015-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84330516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7